Proactive London's Emma Ulker presents her research on Shield Therapeutics.
STX is preparing to launch prescription iron replacement treatment Accrufer in the US, a market estimated to be worth US$1.2bn pa, the largest global market for iron replacement treatment.
A self-launch can provide STX with the lion’s share of projected profits, peak sales estimate of up to US$400mln by year six, and is timely given the opportunity to gain traction given the unmet need for a well-tolerated, effective and convenient treatment for Iron Deficiency (ID).